Neoplasms result from the uncontrolled clonal proliferation of abnormal or transformed cells. The early stages of this process are difficult to study because of the lack of sensitive and specific markers of clonal evolution in an experimental system. We have developed a cat model using cellular mosaicism for glucose-6-phosphate dehydrogenase (G-6PD). Our findings confirm that the structural locus for feline G-6-PD is on the X-chromosome and demonstrate that it is randomly inactivated in somatic cells. Heterozygous cats have balanced ratios of G-6-PD enzyme types in peripheral blood cells and hematopoietic progenitors that remain stable over time. In our initial studies, we used the model to analyze the events surrounding marrow failure experimentally induced by selected strains of feline leukemia virus (FeLV). Two G-6-PD heterozygous cats, one F1 male hybrid and one domestic cat were infected with FeLV (C or KT) and developed pure red cell aplasia (PRCA). Colonies arising from the more mature erythroid colony-forming cell were not detected in marrow culture of anemic animals although erythroid bursts persisted, suggesting that the differentiation of early erythroid progenitors (BFU-E) was inhibited in vivo. The ratio of G-6-PD types in hematopoietic progenitors and peripheral blood cells from the heterozygous cats did not change when the animals developed PRCA. Thus, the anemia did not result from the clonal expansion of a transformed myeloid stem cell. With this experimental approach, one may prospectively assess clonal evolution and cellular interactions in other FeLV-induced diseases.
Introduction
Environmental toxins, drugs, radiation, and viruses have been implicated in the pathogenesis of human malignancy. Although the precise cellular and molecular events that result in the growth advantage of a transformed cell are unknown, host factors may influence the ability of such cells to proliferate in vivo. At the time of clinical presentation and study, most human neoplasms are derived from a single clone (1) . It has therefore been impossible to assess the cellular interactions that permitted the neoplastic clone to expand and dominate. For these reasons, we have developed a model of glucose-6-phosphate dehydrogenase (G-6-PD)' cellular mosaicism in cats to study over time clonal evolution in hematologic diseases experimentally induced by feline leukemia virus (FeLV) .
FeLV is a horizontally transmitted retrovirus that, in the natural setting, causes a spectrum of hematologic disease in cats: lymphosarcoma with mediastinal mass, acute lymphocytic leukemia, myeloid leukemia, erythroleukemia, nonregenerative anemia including pure red cell aplasia (PRCA), and preleukemic myelodysplastic syndromes (2) (3) (4) . As these disorders clinically resemble hematologic malignancy in man, the study of FeLVinduced diseases may be relevant to understanding human oncogenesis.
The enzymes of G-6-PD are useful markers of neoplastic growth and differentiation since they occur naturally and are independent of viral infection and cell transformation. Early in embryogenesis, that portion of one X-chromosome that contains the structural locus for G-6-PD is randomly inactivated in somatic cells of females. Once inactivation occurs, the process is fixed and a single parental G-6-PD allele remains active in each cell and all its progeny. Therefore, women heteroxygous for the usual G-6-PD gene (GdB) and a variant (such as GdA) have some cells that synthesize type B enzyme, while others make type A. No somatic cell makes both G-6-PD types. All tumor cells in a neoplasm originating from a single cell in a G-6-PD heterozygote will have the same single enzyme type, whereas processes arising in multiple cells and normal tissue will have both enzyme types (1) .
Cellular mosaicism for G-6-PD has been used extensively to study the clonal nature and level of progenitor involvement of hematologic neoplasms in man. Such studies have shown that the chronic myeloproliferative diseases result from the clonal expansion of a myeloid stem cell common to granulocytic, erythroid, and megakaryocytic differentiation (5) . Similar data have demonstrated the clonal and stem cell origin of cases of acquired refractory sideroblastic anemia (6) , acute nonlymphocytic leukemia (7) , and aplastic anemia (8) .
Although G-6-PD has been useful in the study of human disease, information regarding cellular mosaicism in animals is relatively sparse. A variant allele at the X-linked phosphoglycerate kinase (PGK) locus was found in feral mice and has been bred into several strains (9) . Clonal evolution of lymphoma has been demonstrated in these animals (10, 11) . Whether the assay to detect PGK is sufficiently sensitive to analyze small numbers of cells (e.g., hematopoietic colonies) has not been reported. G-6-PD heterozygosity exists in the hare, but there is no established model of hematologic malignancy in this system (12, 13) . We have found that domestic cats (Felis catus) and Geoffroy cats (Leopardus geoffroyi) have electrophoretically distinct G-6-PD types. These cats will interbreed (14) to produce female offspring that are obligate G-6-PD heterozygotes. The results of our studies of F1 females confirm previous reports that the structural locus for feline G-6-PD is on the X-chromosome (15 51) .
Sensitivity of the G-6-PD assay. Domestic (d) cat G-6-PD migrated as a single band on isoelectric focusing to pH 6.7. Geoffroy (G) G-6-PD formed several bands with more basic isoelectric points (Fig. 1) Demonstration that the structural locus offeline G-6-PD is on that part of the X-chromosome that is inactivated and that the ratio of G-6-PD activities remains stable. To demonstrate that feline (-6-PD is X-linked, blood cells from the hybrid offspring of a Geoffroy male and multiple female cats were examined. All F, females (n = 20) had both d and G banding. The five F, male cats tested had single d bands, the maternal banding pattern. Of 1,557 hematopoietic colonies tested, 779 were d and 758 were G. Both d and G bands were seen in 20 colonies (1.3%). That the G-6-PD type of hematopoietic colonies was either d or G, but rarely both, demonstrates that only one G-6-PD locus was active in each BFU-E or CFU-GM and its differentiated progeny (Fig. 2) . These observations also prove that feline hematopoietic colonies originate from a single precursor. Table I shows the percentage of colonies containing d-type G-6-PD from 20 F, heterozygotes. The mean is 50%± 11% (SD) and the median is 49%. In each heterozygous cat tested, the ratio of G-6-PD enzyme types in erythroid bursts and GM colonies was similar to the ratios of d/G G-6-PD activities determined for erythrocytes (n = 10), platelets (n = 5), granulocytes (n = 19; Table I), and mononuclear peripheral blood cells (n = 12). Three heterozygous cats have been studied repeatedly for over 1 yr and the d/G ratios in peripheral blood cells and hematopoietic colonies have remained unchanged. Fig. 3 shows colony data in one cat. In a killed control cat, balanced G-6-PD d and G activities were detected in spleen and node. Diffuse bands with equivalent activity in d and G regions were seen with G-6-PD analysis of liver and muscle.
Natural history of FeLV-C/Sarma and KT infection. Two heterozygous cats were infected with FeLV-C/Sarma and one male F, received FeLV-KT. Progressive anemia with reticulocytopenia developed 9 63131  53  35  60  103  76  58  58  ±6  50  63132  60  19  76  57  37  61  68  ±7   50  63133  25  32  44  38  52  42  43  ±8  40   63134  19  39  33  32  59  35  34  ±8  50  63179  4  3  57  28  20  58  58  ±14  60  63689  13  15  46  19  14  58  52  ±13  40  63690  20  16  56  24  19  56  56  ±12  50  63691  28  52  35  35  46  43  39  ±8  50  63775  8  13  38   11  18  38  38  ±14  40  63776  3  9  25  14  18  44  39  ±16  40  63846  11  10  52  8  27  23  34  ±13  40  63848  5  5  50  16   10   62  58  ±18  60  63851  10  16  38  16  17  48  44   ±13  50  64013  9  13  41  17  15  53  48  ±14  64029  13  14  48  13  17   43  46  ±14  40  64030  6  3  67  19  15  56  58  ±16  50   64031  17  5  77  17  17  50  61  ±14  50   64146  3  7  30  12  12  50  44   ±18  50  64147  4  8  33  17  13  57  50  ±16  50  64337  1  1  50  12  4   75  72  ±24  50   Mean  48  51  50±11 (SD)   136 Abkowitz, Ott, Nakamura, Steinmann, Fialkow, and Adamson Sarma to induce PRCA (Fig. 6 ). In this domestic cat, however, the number of BFU-E detectable in culture decreased late in its disease course. At postmortem examination, thymic atrophy and mild diffuse adenopathy were evident. Histopathology demonstrated marrow hypocellularity, depletion of cells in the paracortical and cortical regions of lymph nodes, and less developed follicles in the spleen. The causes of death, feline infectious peritonitis (cat 63530) and nonbacterial pneumonitis (cat 63775), were consistent with immunologic suppression induced by FeLV (3, 25) . The third hybrid cat (63776) was killed when anemic (Hct = 10) and while clinically healthy. Except for mild atrophy of villi and hyperplasia of the crypt epithelium in the small bowel, nonhematopoietic tissues from this cat were normal.
G-6-PD determinations in F, heterozygous cats with PRCA. The G-6-PD types of erythroid bursts and GM colonies obtained from the two heterozygous cats with PRCA are shown in Table II . Both cats remained balanced heterozygotes throughout the study. Variations in d/G ratios are not statistically significant (P > 0.4) and most likely reflect the small numbers of colonies examined at each data point. Ratios of G-6-PD d and G activities in serial preparations of erythrocytes, platelets, granulocytes, and peripheral blood mononuclear cells ranged between 40:60 and 50:50.
ER+ cells and mitogen-stimulated nonadherent lymphocyte preparations also showed nearly equal G-6-PD activities. However, lymphocytes from infected cats did not numerically expand with Con A. Therefore, following the 3-d adherence procedure and mitogen exposure, residual cells were at best 95% lymphocytes by morphologic criteria.
Postmortem specimens were obtained from one cat (63776) for G-6-PD study. Balanced activity of d and G were seen in spleen, spleen mononuclear cells, lymph nodes, liver and muscle. (16, 17, 22, 26) . It is associated with normal granulocyte and platelet counts and, in some animals, myelofibrosis (22) . Although the mechanism by which erythropoiesis is inhibited is not clear, several possibilities are apparent. First, virus might infect and lyse erythroid stem cells (e.g., CFU-E) or erythroblasts or might inhibit their subsequent differentiation. Second, virusinfected accessory cells (e.g., lymphocytes) might interfere with erythropoiesis directly via cell-cell interaction or indirectly via production of humoral products. This latter consideration would be consistent with the tropism of this retrovirus for lymphocytes and postulated mechanisms of PRCA in man (27) (28) (29) . In addition, infection with FeLV might result in the clonal proliferation of a hematopoietic stem cell that has lost its capacity for erythroid differentiation. Consistent with this, human PRCA has been found as a preleukemic illness and as a manifestation of myelodysplastic syndromes (30 In addition to determining whether feline PRCA is a clonal disease, we analyzed the effect of in vivo FeLV infection on the number of hematopoietic progenitors. As cats developed anemia, CFU-E were no longer detected in marrow cell culture. However, essentially normal numbers of erythroid bursts remained in three F, hybrid cats and one domestic cat with experimentally induced PRCA. These data suggest that erythropoiesis is inhibited in vivo subsequent to the BFU-E. That BFU-E are able to differentiate to erythroid bursts in vitro implies that the in vivo inhibition is potentially reversible. Inhibition at the CFU-E or proerythroblast level of differentiation would be consistent with the morphology of marrow aspirates that suggests persisting proerythroblasts. As feline CFU-E are detectable as well-hemoglobinized colonies by day 3 in culture, it is likely that there are few cell divisions between CFU-E and erythroblasts in cats. This implies that CFU-E may not be expressed in vitro as recognizable erythroid colonies if the hemoglobinization of developing proerythroblasts were impaired.
Our observations contrast the results of other groups. In studies by Onions et al. (16) and Testa et al. (17) , the number of BFU-E detected in marrow cultures from neonatal cats decreased 2-3 wk following infection with FeLV-C/Sarma and the hematocrit decreased at 6-7 wk. Similar results were obtained by Gasper et al. (26) in studies of PRCA in steroidsuppressed adolescent domestic cats infected with FeLV-KT. These authors postulated a direct effect of virus on early erythroid progenitors that resulted in a decline in subsequent erythropoiesis and produced severe anemia. The reasons for the differences between our results and those previously reported are presently unknown.
More importantly, however, we have described an experimental system in which issues such as clonal dominance in neoplasia and the influence of virus on hematopoietic precursor number and differentiation may be addressed. As the G-6-PD type of a cell is not related to a viral disease process or transforming event, but is fixed in embryogenesis, the analysis of G-6-PD type independently evaluates clonal evolution. Hybrid cats become viremic with FeLV and develop clinical disease similar to naturally and experimentally infected domestic cats. G-6-PD heterozygous animals may be studied repeatedly over time so that each animal serves as its own control. As an initial application of this model of G-6-PD cellular mosaicism, we have shown that FeLV-induced PRCA does not result from the clonal expansion of an abnormal myeloid stem cell. This model should be applicable to the study of clonal evolution in vivo and the interactions of normal and neoplastic cells in vitro in other experimental disease states.
